At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 13 enrolled
Drug / intervention
Emapalumab-Lzsg 5 MG/ML [Gamifant]drug
Likely dose
Emapalumab-Lzsg 5 MG/ML [Gamifant]from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Single Arm, Multi-Centre, Post-authorization Study to Describe the Safety and Efficacy of Emapalumab for the Treatment of Primary Hemophagocytic Lymphohistiocytosis in Treatment Experienced Chinese Patients
In Brief
A Phase 4 clinical trial evaluating Emapalumab-Lzsg 5 MG/ML [Gamifant] for Primary Hemophagocytic Lymphohistiocytosis. Completed, enrolled 13 participants across 7 sites.
Detailed Summary
The goal of this post-authorization study is to describe safety and efficacy of emapalumab in treatment experienced Chinese patients with pHLH.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--
Timeline
Phase 4CompletedFinished
2023202420252026
Enrollment StartFeb 2023
First PostedFeb 2023
Primary CompletionFeb 2025
Study CompletionAug 2025
TodayJul 2026
First PostedFeb 24, 2023
Enrollment StartFeb 3, 2023
Primary CompletionFeb 21, 2025
Study CompletionAug 8, 2025
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 3.4 years ago
Interventions
Emapalumab-Lzsg 5 MG/ML [Gamifant]drug
iv